An experimental study in Science Advances shows that statins, primarily fluvastatin in these experiments, may promote low-level muscle myopathy by reducing isoprenoid-dependent protein prenylation rather than by cholesterol lowering. In primed muscle cells and mouse models, impaired YAP signaling, reduced glycolysis, NLRP3/caspase-1 activation, and nuclear FOXO accumulation increased atrogin-1, reduced protein synthesis, and weakened muscle function.